THU327 Characterization Of New Onset Diabetes Mellitus Concurrent With COVID-19; A Single Institution Experience

Abstract

Abstract Disclosure: T. Haque: None. M. Gaddis: None. R. Asad: None. S. Simon: None. B.M. Drees: None. Objective: The global pandemic of novel SARS-COV2 virus causing Covid-19 infection, is reported to lead to development of new onset diabetes mellitus (DM). This study describes the types of DM following Covid-19 infection, the patient characteristics and the disease course up to 12 months. Methods: A database of patients with DM treated at the institution was searched for a positive PCR Covid-19 test between March 1, 2020, and November 30, 2021. Charts were manually reviewed for diagnosis of co-morbidities, laboratory results, medications, disposition, and verification of type of DM. Outcomes data were collected at 0, 6, and 12 months. Results: Among 1643 Covid-19 positive patients with DM, 96 were diagnosed with new onset DM. There were 42% Black, 24% White, and 23% Hispanic; 94 had type 2 DM and two had type 1 DM. Average age was 50; half were women. Patients with more severe Covid (inpatient and ER visits) were more likely to require insulin, multiple DM medications, and had higher HbA1c levels. Insulin use and multiple DM medications decreased over time (25% and 25% at diagnosis; 10% and 18% at 12 months, respectively). HbA1c decreased over time (9.1% at diagnosis and 7.3% at 12 months). One-year follow-up was available on 73 patients, of whom 19 were on no medications for DM. Conclusion: New onset diabetes mellitus following Covid-19 infection is common and predominantly type 2 DM. However, glucose levels tend to improve over time requiring less medication, with 26% requiring no DM medications at one year. Presentation: Thursday, June 15, 2023